RNA editing is a much more accessible approach Elverum said if you think through what a patient wants in terms of the risks they want to take or even what a payer wants in terms of how medicines are paid for The company has not disclosed what other diseases it plans to work on outside of AATD but said its medicines would target both AIRNA has a uniquely powerful technology to maximize the therapeutic properties of RNA editing medicines and achieve the vision of restoring a patients health Novak said in a statement